Windtree Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Istaroxime, a late-stage dual mechanism agent, is advancing as a lead therapy for cardiogenic shock, showing strong efficacy in phase II studies with significant improvements in blood pressure, cardiac function, and renal health. Phase III trials are planned, with global partnerships and commercialization strategies under discussion.
-
Istaroxime showed rapid, significant improvements in blood pressure, cardiac output, and renal function in phase II studies for cardiogenic shock, with a favorable safety profile and strong physician interest. The company is prioritizing this indication for its faster regulatory path and high unmet need, while advancing acute heart failure and next-generation assets through partnerships.
-
Istaroxime showed rapid, significant improvements in blood pressure, cardiac output, and renal function in phase II cardiogenic shock studies, with a favorable safety profile and strong physician interest. The company is advancing to studies in more severe patients and preparing for phase 3 trials, while actively pursuing partnerships and funding.